A study to find a suitable dose of ASP5834 in adults with solid tumors

2025-522082-29-00 · tracked via the Priya Life Science EU tracker

Sponsor

Astellas Pharma Inc.

Sponsor type

Pharmaceutical company

Therapeutic area

Neoplasms

Decision date

28/11/2025

Enrollment target

Sites

Spain, France

Condition studied

Locally advanced (unresectable) or metastatic solid tumor malignancies who harbor a KRAS mutation (G12V, G12D, G12C, G12A, G12R or G13D mutation) or KRAS amplification

Eligibility

Age group

18-64 years, 65+ years

Sex

Female, Male

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-522082-29-00 on CTIS ↗ ← All trials in the EU